💰 The deal was valued at $48 million.
🔬 SignalChem Biotech specializes in bioactive enzymes used in research and drug development.
🌐 The acquisition strengthens Sino Biological’s expertise in enzyme production and related contract research services.
🚀 Sino Biological aims to expand its presence in bioactive recombinant proteins through this acquisition.
Introduction:
China-based biotech company Sino Biological has completed its acquisition of SignalChem Biotech, a Vancouver-based company specializing in bioactive enzymes. The deal was valued at $48 million. Sino Biological aims to strengthen its presence in bioactive recombinant proteins and related contract research services through this acquisition.
- SignalChem Biotech focuses on bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin, and epigenetic enzymes.
- Over the past two decades, SignalChem Biotech has established proprietary production and quality control platforms for the development and production of high-quality bioactive enzyme proteins, which will enhance Sino Biological’s existing technology platforms.
- The acquisition strengthens Sino Biological’s presence in bioactive recombinant proteins and related contract research services.
- SignalChem Biotech brings exclusive expertise in enzyme production to Sino Biological.
- This acquisition will enable Sino Biological to provide enhanced support to scientists in basic research through drug discovery and development.
Conclusion:
Sino Biological has successfully acquired SignalChem Biotech, a Vancouver-based bioactive enzyme company, in a $48 million deal. This acquisition will allow Sino Biological to expand its capabilities in bioactive recombinant proteins and contract research services, thanks to the expertise that SignalChem Biotech brings in enzyme production. Sino Biological aims to provide improved support to scientists in various stages of research and drug development.
